143 related articles for article (PubMed ID: 30593126)
1. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.
Mota JM; Sousa LG; Braghiroli MI; Siqueira LT; Neto JEB; Chapchap P; Hoff AAO; Hoff PM
Medicine (Baltimore); 2018 Dec; 97(52):e13517. PubMed ID: 30593126
[TBL] [Abstract][Full Text] [Related]
2. High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma - A Single Center Case Series.
Schwarzlmueller P; Corradini S; Seidensticker M; Zimmermann P; Schreiner J; Maier T; Triebig A; Knösel T; Pazos M; Pfluger T; Weigand I; Belka C; Ricke J; Reincke M; Schmidmaier R; Kroiss M
Horm Metab Res; 2024 Jan; 56(1):30-37. PubMed ID: 37748508
[TBL] [Abstract][Full Text] [Related]
3. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Pak C; Yoon S; Lee JL; Yun T; Park I
Curr Oncol Rep; 2024 Apr; 26(4):307-317. PubMed ID: 38381366
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.
Uehara S; Naganuma A; Furuichi N; Furusawa A; Kaburagi T; Naruse H; Tomaru S; Sano N; Suzuki Y; Masuda T; Hoshino T; Yasuoka H; Tanaka Y; Saito S; Hatanaka T; Kakizaki S
Intern Med; 2023 Nov; 62(21):3151-3156. PubMed ID: 36927965
[TBL] [Abstract][Full Text] [Related]
5. Durable response to pembrolizumab in microsatellite instability-high advanced adrenocortical carcinoma.
Senda M; Hashimoto K; Shindo T; Kobayashi K; Tanaka T; Masumori N
IJU Case Rep; 2023 Nov; 6(6):382-385. PubMed ID: 37928286
[TBL] [Abstract][Full Text] [Related]
6. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner.
Warde KM; Smith LJ; Liu L; Stubben CJ; Lohman BK; Willett PW; Ammer JL; Castaneda-Hernandez G; Imodoye SO; Zhang C; Jones KD; Converso-Baran K; Ekiz HA; Barry M; Clay MR; Kiseljak-Vassiliades K; Giordano TJ; Hammer GD; Basham KJ
Nat Aging; 2023 Jul; 3(7):846-865. PubMed ID: 37231196
[TBL] [Abstract][Full Text] [Related]
7. Ten-Patient Trial: Remarkable Responses in Pediatric Cancers.
Mardis ER
Clin Cancer Res; 2023 Dec; 29(23):4701-4702. PubMed ID: 37733329
[TBL] [Abstract][Full Text] [Related]
8. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Baba K; Tanaka H; Sakamoto H; Shiratori T; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Tasaka S
Thorac Cancer; 2019 Feb; 10(2):369-372. PubMed ID: 30600919
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.
Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I
Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM; Pabla S; Nesline MK; Glenn ST; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Bshara W; Khalil M; Dy GK; Madden KG; Shirai K; Dragnev K; Tafe LJ; Zhu J; Labriola M; Marin D; McCall SJ; Clarke J; George DJ; Zhang T; Zibelman M; Ghatalia P; Araujo-Fernandez I; de la Cruz-Merino L; Singavi A; George B; MacKinnon AC; Thompson J; Singh R; Jacob R; Kasuganti D; Shah N; Day R; Galluzzi L; Gardner M; Morrison C
J Immunother Cancer; 2019 Jan; 7(1):18. PubMed ID: 30678715
[TBL] [Abstract][Full Text] [Related]
13. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Pujol JL; Greillier L; Audigier-Valette C; Moro-Sibilot D; Uwer L; Hureaux J; Guisier F; Carmier D; Madelaine J; Otto J; Gounant V; Merle P; Mourlanette P; Molinier O; Renault A; Rabeau A; Antoine M; Denis MG; Bommart S; Langlais A; Morin F; Souquet PJ
J Thorac Oncol; 2019 May; 14(5):903-913. PubMed ID: 30664989
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
16. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
17. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
[TBL] [Abstract][Full Text] [Related]
18. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
19. Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
Uenami T; Ishijima M; Kanazu M; Kurebe H; Edahiro R; Nishida K; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Ann Transl Med; 2018 Nov; 6(22):444. PubMed ID: 30596074
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.
Zhang W; Zhang J; Zhang Z; Guo Y; Wu Y; Wang R; Wang L; Mao S; Yao X
Transl Oncol; 2019 Mar; 12(3):485-492. PubMed ID: 30594037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
